Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Adjuvant TKIs in NSCLC: what can we learn from RADIANT?

Nature Reviews Clinical Oncology volume 12, pages 689–690 (2015)Cite this article

Subjects

In the RADIANT study, no difference in disease-free survival was observed for patients with non-small-cell lung cancer (NSCLC) treated with erlotinib versus placebo in the adjuvant setting. Further biomarker studies are awaited to determine whether patients with NSCLC can benefit from adjuvant therapy with tyrosine kinase inhibitors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis from the LACE Collaborative Group. J. Clin Oncol. 26, 3552–3559 (2008).

    Article  Google Scholar 

  2. Tsao, M. S. et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).

    Article  CAS  Google Scholar 

  3. Hirsch, F. R. et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J. Clin. Oncol. 24, 5034–5042 (2008).

    Article  Google Scholar 

  4. Kelly, K. et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.61.8918 (2015).

  5. Janjigian, Y. Y. et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J. Thorac. Oncol. 6, 569–575 (2011).

    Article  Google Scholar 

  6. Pennel, N. A. et al. SELECT: a multicentre phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a7514 (2014).

    Article  Google Scholar 

  7. Goss, G. D. et al. Gefitinib versus placebo in completely resected non-small cell lung cancer: result of the NCIC-CTG BR 19 Study. J. Clin. Oncol. 31, 3320–3326 (2013).

    Article  CAS  Google Scholar 

  8. Yang, J. C. et al. Afatinib versus cisplatin based chemotherapy for EGFR mutation positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6). Analysis of overall survival data from two randomized phase III trials. Lancet Oncol. 16, 141–151 (2015).

    Article  CAS  Google Scholar 

  9. National Cancer Institute. The ALCHEMIST lung cancer trials [online], (2014).

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, University of Colorado, 12801 East 17th Avenue, Aurora, 80045, CO, USA

    Fred R. Hirsch & Paul A. Bunn Jr

Authors
  1. Fred R. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul A. Bunn Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fred R. Hirsch.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hirsch, F., Bunn, P. Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. Nat Rev Clin Oncol 12, 689–690 (2015). https://doi.org/10.1038/nrclinonc.2015.202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.202

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing